Tuberculosis Trial Design: FDA/Company Endpoint Talks Go Public At Cmte.

The approval pathway for drugs to treat multi-drug resistant tuberculosis became somewhat clearer for sponsors as FDA's Anti-Infective Drugs Advisory Committee weighed in on clinical trial endpoints at a June 3 meeting